Skip to main content
Molecular Therapy logoLink to Molecular Therapy
. 2022 Oct 18;30(11):3499. doi: 10.1016/j.ymthe.2022.10.001

The Amyloid Inhibitor CLR01 Relieves Autophagy and Ameliorates Neuropathology in a Severe Lysosomal Storage Disease

Antonio Monaco, Veronica Maffia, Nicolina Cristina Sorrentino, Irene Sambri, Yulia Ezhova, Teresa Giuliano, Vincenzo Cacace, Edoardo Nusco, Maria De Risi, Elvira De Leonibus, Thomas Schrader, Frank-Gerrit Klärner, Gal Bitan, Alessandro Fraldi
PMCID: PMC9637752  PMID: 36261045

Main text

(Molecular Therapy 28, 1167–1176; April 2020)

In the originally published version of this article, an error was made during the assembly of Figure 4A: the cropped image used as representative of "striatum anti-GFAP WT + saline" was inadvertently taken from the folder containing the cropped images of "striatum anti-GFAP WT + CLR01" fields, instead of from the correct folder (cropped images of “striatum anti-GFAP WT + saline” fields). Therefore, two partial overlapping cropped images of the same field (striatum anti-GFAP WT + CLR01) were used in the panel.

The correct version of Figure 4A is included here. The authors apologize for the error.

graphic file with name gr4ac.jpg

Figure 4A. CLR01 Treatment Ameliorates Neuropathological Signs in MPS-IIIA Mice (corrected)


Articles from Molecular Therapy are provided here courtesy of The American Society of Gene & Cell Therapy

RESOURCES